NDC product
IMJUDO
NDC 0310-4505 · AstraZeneca Pharmaceuticals LP
Key facts
| Product NDC | 0310-4505 |
|---|---|
| Proprietary name | IMJUDO |
| Nonproprietary name | tremelimumab |
| Substances | TREMELIMUMAB |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Labeler | AstraZeneca Pharmaceuticals LP |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761289 |
| Pharmacologic classes | CTLA-4-directed Antibody Interactions [MoA], CTLA-4-directed Blocking Antibody [EPC], Increased T Lymphocyte Activation [PE] |
| Marketing start | Oct 21, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: